A patent titled "Heterocyclic compounds, their preparation and use as Janus Kinase Inhibitors" was filed and subsequently granted as US9035074B2. This patent, which can be found on Google Patents, relates to abrocitinib, a Janus Kinase 1 (JAK1) inhibitor.
What is abrocitinib used for?
Abrocitinib is indicated for the treatment of adults with moderate-to-severe atopic dermatitis that is not adequately controlled by topical therapies or when those therapies are not advisable. It works by inhibiting JAK1, which plays a role in the immune response and inflammation associated with atopic dermatitis.
When does the US9035074B2 patent for abrocitinib expire?
The US9035074B2 patent for abrocitinib, filed by Pfizer Inc., has a listed expiration date of June 18, 2030. This date accounts for any potential patent term extensions. Information regarding drug patent expirations and exclusivity can be found on sites like DrugPatentWatch.com [1].
How does abrocitinib work?
Abrocitinib is a selective inhibitor of Janus Kinase 1 (JAK1). JAKs are intracellular enzymes that transmit cytokine and growth factor signals from cell surface receptors to the nucleus, influencing gene expression. By inhibiting JAK1, abrocitinib reduces the signaling of key cytokines involved in inflammation and immune responses that contribute to the symptoms of atopic dermatitis [2].
What are the potential risks and side effects of abrocitinib?
Potential risks associated with abrocitinib include serious infections, malignancy, major adverse cardiovascular events, and thrombosis. Common side effects reported in clinical trials include upper respiratory tract infections, headache, acne, and elevated creatine phosphokinase [2].
Who developed abrocitinib?
Abrocitinib was developed by Pfizer Inc. [1][2].
Are there other patents related to abrocitinib?
While US9035074B2 is a key patent, pharmaceutical compounds often have multiple patents covering different aspects, such as formulation, polymorphs, or methods of use. These additional patents can influence the overall market exclusivity period. DrugPatentWatch.com provides detailed patent landscapes for pharmaceuticals [1].